Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Business Wire November 7, 2023

bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 2, 2023

bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million

Business Wire October 30, 2023

bluebird bio to Host Third Quarter 2023 Financial Results Conference Call

Business Wire October 24, 2023

bluebird bio Announces September Investor Events

Business Wire September 5, 2023

bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease

Business Wire August 16, 2023

bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Business Wire August 8, 2023

bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update

Business Wire July 25, 2023

bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

Business Wire June 21, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

PR Newswire May 10, 2023

bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress

Business Wire May 9, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

PR Newswire May 2, 2023

bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events

Business Wire April 27, 2023

bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

Business Wire April 24, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

PR Newswire April 19, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of bluebird bio, Inc. - BLUE

Newsfile April 14, 2023

bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

Business Wire March 29, 2023

bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

Business Wire January 18, 2023

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

Business Wire January 18, 2023

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 9, 2023